News Search Results
Apr 24, 2026, 10:40 ET RIMAN conecta os mercados da APAC em Macau com estratégia, inovação e lançamento de novos produtos
também destacou sua linha de pesquisa durante o evento. Dr. Hee-sik Kim, CTO da ASK LABS e pesquisador do Korea Research Institute of Bioscience and Biotechnology, apresentou um biomaterial de origem vegetal derivado de uma cepa proprietária de clorela encontrada em Jeju. Este material está em desenvolvimento
More news about: RIMAN
Apr 24, 2026, 09:00 ET Circular Genomics Appoints World-Renowned Expert in Neurochemistry and Alzheimer's Fluid Biomarkers Dr. Henrik Zetterberg to Scientific Advisory Board
DiseasesSAN DIEGO, April 24, 2026 /PRNewswire/ -- Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine through brain-derived circular RNA (circRNA) biomarkers, today announced
More news about: Circular Genomics
Apr 24, 2026, 09:00 ET Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
program reached this critical milestone in under 12 months.This milestone also serves as a powerful testament to the maturity of the local biotechnology ecosystem and research infrastructure., reflecting ADIO's Health, Endurance, Longevity and Medicine (HELM) cluster's role in attracting and supporting
More news about: Insilico Medicine
Apr 24, 2026, 08:00 ET Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.For more information, please visit: www.scinai.comCompany
More news about: Scinai Immunotherapeutics Ltd.
Apr 24, 2026, 08:00 ET Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotechnology company, announced that clinical results have demonstrated significant cognitive improvement and preservation of brain function in patients with
More news about: Miracell
Apr 24, 2026, 07:30 ET HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected Bloomberg to
More news about: HanchorBio Inc.
Apr 24, 2026, 02:58 ET CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair
Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models.TAICHUNG,
More news about: China Medical University Hospital
Apr 23, 2026, 17:54 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit- Hagens Berman
[email protected], Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 23, 2026, 16:15 ET Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million
More news about: Nektar Therapeutics
Apr 23, 2026, 11:01 ET Genomics Services Market Set to Reach $24.0 Billion by 2033, Growing at 11.2% CAGR
disease diagnostics.By End User: The primary end users of genomics services include pharmaceutical and biopharmaceutical companies, biotechnology firms, academic and government research institutions, contract research organizations (CROs), and hospitals and diagnostic laboratories. Pharmaceutical
More news about: Allied Market Research
Apr 23, 2026, 10:42 ET Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
Apr 23, 2026, 10:00 ET James Udelson, MD, Honored with Prestigious Paul Dudley White Award by the American Heart Association
leading global contract research organization specializing exclusively in cardiovascular clinical trials. CCS partners with medical technology, biotechnology and pharmaceutical companies to design and execute high–quality clinical research across cardiovascular device and drug trials in heart failure, cardiomyopathies,
More news about: Cardiovascular Clinical Sciences
Apr 23, 2026, 09:24 ET AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling
regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and
More news about: AdvisorShares
Apr 23, 2026, 09:00 ET Theradaptive Announces Final Patient Enrolled in RESTORE Feasibility Study Evaluating OsteoAdapt® DE in Dental Procedures
Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced the successful treatment of the 45th and final
More news about: Theradaptive
Apr 23, 2026, 09:00 ET Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
with established commercial operations typical of a specialty pharmaceutical company and an exciting development pipeline often associated with a biotechnology firm" said A.J. Kazimi, CEO of Cumberland. "This transaction unlocks value for our shareholders and enables us to focus on the large market opportunities
More news about: Cumberland Pharmaceuticals Inc.
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
CAMBRIDGE, Mass., April 23, 2026 /PRNewswire/ -- CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today announced the dosing of the first patient in the Phase 1/2 clinical trial of MT-304, an
More news about: CREATE Medicines, Inc.
Apr 23, 2026, 08:00 ET FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION
BASEL, Switzerland, April 23, 2026 /PRNewswire/ -- Ferrosa Therapeutics AG ("FERROSA"), a Swiss biotechnology company developing a first-in-class bispecific antibody to treat anemia of inflammation, announced today a seed financing of USD 3.5 Million by
More news about: Ferrosa Therapeutics AG
Apr 23, 2026, 08:00 ET FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION
BASEL, Switzerland, April 23, 2026 /PRNewswire/ -- Ferrosa Therapeutics AG ("FERROSA"), a Swiss biotechnology company developing a first-in-class bispecific antibody to treat anemia of inflammation, announced today a seed financing of USD 3.5 Million by
More news about: Ferrosa Therapeutics AG
Apr 23, 2026, 08:00 ET Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
CAMBRIDGE, Mass., April 23, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has
More news about: Repertoire Immune Medicines
Apr 23, 2026, 08:00 ET Immunic, Inc. Announces 1-for-10 Reverse Stock Split
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect
More news about: Immunic, Inc.
Apr 23, 2026, 07:46 ET RIMAN Connects APAC Markets in Macau Through Strategy, Innovation, and New Product Reveal
highlighted its research pipeline during the event. Dr. Hee-sik Kim, CTO of ASK LABS and a researcher at the Korea Research Institute of Bioscience and Biotechnology, introduced a plant-based bio-material derived from a proprietary chlorella strain found in Jeju. This material has been under development for approximately
More news about: RIMAN
Apr 23, 2026, 07:32 ET RIMAN Connects APAC Markets in Macau Through Strategy, Innovation, and New Product Reveal
highlighted its research pipeline during the event. Dr. Hee-sik Kim, CTO of ASK LABS and a researcher at the Korea Research Institute of Bioscience and Biotechnology, introduced a plant-based bio-material derived from a proprietary chlorella strain found in Jeju. This material has been under development for approximately
More news about: RIMAN
Apr 23, 2026, 07:30 ET Mikart and Benuvia Announce Strategic Co-Marketing Partnership to Deliver End-to-End Controlled Substance Development and Finished Drug Product Manufacturing Solutions
through finished drug product manufacturing. By aligning their expertise, the companies aim to deliver a seamless experience for pharmaceutical and biotechnology partners seeking efficiency, quality, and regulatory excellence. The partnership is specifically designed to enhance customer value by streamlining
More news about: Mikart, LLC
Apr 23, 2026, 07:00 ET Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Apr 23, 2026, 03:00 ET SkylineDx to Present Data on Precision Molecular Diagnostics Advances in Cutaneous Squamous Cell Carcinoma at 22nd EADO Congress
practice, demonstrating how precision tools can enhance patient care and guide treatment decisions." About SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx